4//SEC Filing
Farrell Geraldine T 4
Accession 0001572426-17-000020
CIK 0001618561other
Filed
Aug 1, 8:00 PM ET
Accepted
Aug 2, 9:22 PM ET
Size
14.9 KB
Accession
0001572426-17-000020
Insider Transaction Report
Form 4
Farrell Geraldine T
VP Operations, General Counsel
Transactions
- Disposition to Issuer
Restricted Share Units
2017-07-31$6.59/sh−30,000$197,850→ 0 totalExercise: $0.13From: 2017-07-01Exp: 2021-07-01→ Ordinary Shares (30,000 underlying) - Disposition to Issuer
Restricted Share Units
2017-07-01$6.59/sh−4,678$30,851→ 0 totalExercise: $0.13Exp: 2020-07-01→ Ordinary Shares (4,678 underlying) - Disposition to Issuer
Option to Purchase Shares
2017-07-31−20,000→ 0 totalExercise: $15.00Exp: 2020-05-18→ Ordinary Shares (20,000 underlying) - Disposition to Issuer
Ordinary Shares
2017-07-31$6.72/sh−18,980$127,546→ 0 total - Disposition to Issuer
Ordinary Shares
2017-07-31$6.72/sh−33,180$222,970→ 0 total(indirect: Geraldine Therese Farrell & Andrew John Benston <Bulla Bulla Family A/C>)
Footnotes (5)
- [F1]Disposed of pursuant to a transaction agreement between the Issuer, Zoetis Inc. ("Zoetis") and Zoetis Belgium S.A., a wholly-owned subsidiary of Zoetis ("Bidco"), pursuant to which Bidco acquired the Issuer (the "Acquisition")
- [F2]The reporting person and her spouse have shared voting and dispositive power with respect to these reported securities.
- [F3]This restricted share unit, which would have vested and become convertible as to 10,000 shares on each of 7/1/18, 7/1/19 and 7/1/20, in each case subject to payment of the nominal value per share of $0.125 to the Issuer within 30 days of vesting, was cancelled in the Acquisition in exchange for a cash payment equal to $197,850. This amount represents the difference between such nominal value per share and the $6.72 consideration per share payable in connection with in the Acquisition, multiplied by the number of shares issuable on conversion of the restricted share unit.
- [F4]This restricted share unit, which would have vested and become convertible as to 2,339 shares on each of 7/1/18 and 7/1/19, in each case subject to payment of the nominal value per share of $0.125 to the Issuer within 30 days of vesting, was cancelled in the Acquisition in exchange for a cash payment equal to $30,851.41. This amount represents the difference between such nominal value per share and the $6.72 consideration per share payable in connection with in the Acquisition, multiplied by the number of shares issuable on conversion of the restricted share unit.
- [F5]This option, which was vested as to 14,000 shares and would have vested as to 1,000 shares on each of 9/30/17, 12/31/17, 3/31/18, 6/30/18, 9/30/18 and 12/31/18, was cancelled in the Acquisition in exchange for no cash payment because the $15.00 exercise price per share exceeded the $6.72 consideration per share payable in connection with in the Acquisition.
Documents
Issuer
Nexvet Biopharma plc
CIK 0001618561
Entity typeother
Related Parties
1- filerCIK 0001632385
Filing Metadata
- Form type
- 4
- Filed
- Aug 1, 8:00 PM ET
- Accepted
- Aug 2, 9:22 PM ET
- Size
- 14.9 KB